What does “more effective” mean for Cosentyx (secukinumab)?
Cosentyx effectiveness depends on the condition being treated (psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis) and what outcome matters (skin clearance, joint symptom improvement, radiographic slowing, or symptom scores). Without specifying the disease and the comparator drug(s), it’s not possible to say broadly that Cosentyx is “more effective” than all other medications.
Is Cosentyx more effective than TNF inhibitors for psoriasis or psoriatic arthritis?
For many patients, biologics that target different immune pathways (like IL-17A for Cosentyx versus TNF inhibitors) can produce strong responses, but whether Cosentyx is “more effective” varies by the specific comparator, patient population, and endpoint used in the studies (for example, percent reaching PASI 75/90 for skin, or ACR responses for joints).
How does Cosentyx compare with other IL-17 or IL-23 drugs?
Cosentyx targets IL-17A. Other psoriasis and psoriatic arthritis biologics include:
- Other IL-17 pathway drugs (also often strong for skin outcomes)
- IL-23 pathway drugs (frequently high rates of skin clearance)
Which one is “more effective” depends on the outcome and whether patients are biologic-naïve or have had prior treatment failures. In real-world practice, clinicians often pick based on prior response, comorbidities, route/timing, safety profile, and patient preference rather than assuming one drug is universally best.
What about ankylosing spondylitis and non-radiographic axial spondyloarthritis?
Axial spondyloarthritis outcomes can include improvements in pain and function and reduction in inflammation measures. Cosentyx can be effective, but comparative “more effective” claims again depend on the exact comparator (other biologics) and the endpoints reported.
If you switch drugs, does Cosentyx work after another biologic?
Effectiveness after switching is often lower than first-time biologic success rates, but many patients still respond when switching within or across mechanisms. Whether Cosentyx is better than alternatives after prior treatment depends on the prior drug class used and on the individual study comparisons.
What side effects or risks might influence the choice versus “effectiveness”?
For IL-17A inhibitors like Cosentyx, safety tradeoffs can matter alongside efficacy. For example, IL-17 pathway blockade is associated with specific infection risks and can affect certain conditions; this can influence whether a clinician chooses Cosentyx over another biologic even if multiple options have similar effectiveness.
If you tell me your condition, I can answer more precisely
If you share:
1) which disease you mean (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, etc.),
2) what other medication(s) you’re comparing against, and
3) what outcome you care about (skin clearance vs joint symptoms),
I can give a more direct “more effective vs less effective” comparison based on the relevant evidence and endpoints.
Sources
No sources were provided with the information needed to make a comparative effectiveness claim, and DrugPatentWatch.com is not directly applicable to deciding comparative effectiveness across drugs for specific indications.